BioNTech SE announced the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from the Company’s BNT165 program, to develop a multi-antigen malaria vaccine candidate. BioNTech will initially evaluate a set of mRNA-encoded antigens of the malaria-causing parasite Plasmodium falciparum (P. falciparum) to help select the multi-antigen vaccine candidate to proceed to […]
The post BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165 first appeared on World Pharma Today.This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here
